Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials.

Saved in:
Bibliographic Details
Title: Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials.
Authors: Pasalic D; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., McGinnis GJ; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Fuller CD; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Grossberg AJ; Oregon Health & Science University, Portland, OR, USA., Verma V; Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA., Mainwaring W; Baylor College of Medicine, Houston, TX, USA., Miller AB; The University of Texas Health Science Center, McGovern Medical School, Houston, TX, USA., Lin TA; The Johns Hopkins University School of Medicine, Baltimore, MD, USA., Jethanandani A; The University of Tennessee Health Science Center, Memphis, TN, USA., Espinoza AF; Baylor College of Medicine, Houston, TX, USA., Diefenhardt M; University of Frankfurt, Frankfurt, Germany; Frankfurt Cancer Institute, Frankfurt, Germany., Das P; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Subbiah V; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Subbiah IM; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jagsi R; University of Michigan, Ann Arbor, MI, USA., Garden AS; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Fokas E; University of Frankfurt, Frankfurt, Germany; Frankfurt Cancer Institute, Frankfurt, Germany; German Cancer Research Center, Heidelberg, Germany; German Cancer Consortium, Frankfurt, Germany., Rödel C; University of Frankfurt, Frankfurt, Germany; Frankfurt Cancer Institute, Frankfurt, Germany; German Cancer Research Center, Heidelberg, Germany; German Cancer Consortium, Frankfurt, Germany., Thomas CR Jr; Oregon Health & Science University, Portland, OR, USA., Minsky BD; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ludmir EB; The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: ebludmir@mdanderson.org.
Source: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2020 Sep; Vol. 136, pp. 176-185. Date of Electronic Publication: 2020 Jul 20.
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Review
Journal Info: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1879-0852
DOI:10.1016/j.ejca.2020.06.015